In Vitro Effects of Tp5 Analogs on E-Rosette Formation and Cell Division

References

• Abiko T, Kumikawa M, Sekino H. Synthesis and effect of two peptide fragments of thymopoietin II on E-rosette forming cells in the uremic state. Chem. Pharm. Bull. 1979; 27: 2233
   PubMed Web of Science ®Google Scholar
• Aiuti F, Fiorilli M, Quinti J, Seminara R, Bosinco L, Galli E, Rossi P, Goldstein G. Thymopoietin pentapeptide treatment of primary immunodeficiences. Lancet 1983; 1: 551
   PubMed Web of Science ®Google Scholar
• Audhya T, Schlesinger D H, Goldstein G. Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides. Biochem. 1981; 20: 619
   Web of Science ®Google Scholar
• Bach J F, Bach M A, Balnot D, Bricas E, Chanriere J, Dardanne M, Fournier C, Plean J M. Thymic serum factor (FTS). Bull. Ins. Pasteur. 1978; 76: 323
   Google Scholar
• Boyum A. Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest. 1968; 21(suppl. 97)29
   Google Scholar
• Cadman E, Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosins cerebinoside. Study of L-1210 and human leukemia cells. J. Clin. Lab. Invest. 1979; 64: 788
   Google Scholar
• Ciardelli T L, Incefy G S, Birr C. Activity of synthetic thymosin alpha 1 C-terminal peptides in the azathioprine E-rosette inhibition assay. Biochem. 1982; 21: 4233
   PubMed Web of Science ®Google Scholar
• Committee of American Rheumatoid Association. 1958 Revision of diagnostic criteria for Rheumatoid Association. Arthr. Rheum. 1959; 2: 16
   PubMed Web of Science ®Google Scholar
• Di Perri T, Pasini F L, Auteri A. Immunokinetics of a single dose of thymopoietin pentapeptide. Immunopharmacol. 1980; 2: 567
   Web of Science ®Google Scholar
• Dupont E, Vandercruys M, Wybran J. Deficient natural killer function in patients receiving immunosuppressive drugs analysis at the cellular level. Cell. Immunol. 1984; 88: 85
   PubMed Web of Science ®Google Scholar
• Felsburg P J, Edelman R, Gilman R H. The active rosette test: Correlation with delayed cutaneous hypersensitivity. J. Immunol. 1976; 116: 1110
   PubMed Web of Science ®Google Scholar
• Fiorilli M, Sirianini M C, Pandolfi F, Quinti J, Tosti J, Aiuti J, Goldstein G. Improvement of natural killer activity and of T-cells after thymopoietin pentapeptide therapy in patient with severe combined immunodeficiency. Clin. Exp. Immunol. 1981; 45: 344
   PubMed Web of Science ®Google Scholar
• Fisz M. Probability theory and mathematical statistics. John Wiley, New York London 1963; 524
   Google Scholar
• Gierco M H, Siegel J, Goel Z. Modulation of human T-lymphocyte rosette formation by autonomic agonists and cyclic nucleotides. J. Allergy Clin. Immunol. 1976; 58: 149
   PubMed Web of Science ®Google Scholar
• Goldstein A L, Low T LK, Thurman G B, Zatz M M, Hall N, Chem J, Hu S K, Naylor P B, McClure J E. Current status of thymosin and other hormones of the thymic gland. Recent Progress in Hormone Research, R O Greep. Francisco Academic Press, New York-London-Toronto-Sydney-San 1981; 37: 369
   Google Scholar
• Goldstein G, Sheid M P, Boyse E A, Schlesinger D H, Van Wauve J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 1979; 204: 1309
   PubMed Web of Science ®Google Scholar
• Jackson D V, Bender R A. Cytotoxic thresholds of vincristine in murine and human leukemia cell line in vitro. Cancer Res. 1979; 39: 4346
   PubMed Web of Science ®Google Scholar
• Janossy G, Tidman N, Papageorgiou E S, Kung P E, Goldstein G. Distribution of T lymphocytes subsets in the human bone marrow and thymus - an analysis with monoclonal antibodies. J. Immunol. 1980; 126: 1608
   Web of Science ®Google Scholar
• Joeffe M J, Sochett E, Pettifor J M, Rabson A R. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function. J. Clin. Lab. Immunol., 8: 69
   PubMedGoogle Scholar
• Kisfaludy L, Nyeki O, Schon I, Denes L, Ember J, Szporny L, Hajos G y, Szende B. Immunoregulating peptides, I. Synthesis and structure-activity relationships of TP5 analogs. Hoppe Seyler's Z Physiol. Chem. 1983; 364: 933
   PubMedGoogle Scholar
• Kook A J, Trainin N. Intracellular events involved in the induction of immune competence in lymphoid cells by a thymus humoral factor. J. Immunol. 1975; 114: 151
   PubMed Web of Science ®Google Scholar
• Kung P C, Goldstein G, Reinherz E L, Schlossman S F. Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 1979; 206: 347
   PubMed Web of Science ®Google Scholar
• Kung P C, Goldstein G. Functional and developmental compartments of human T-lymphocytes. Vox Sanguinis 1980; 39: 121
   PubMed Web of Science ®Google Scholar
• Lau C Y, Wang E Y, Goldstein G. Studies of thymopoietin pentapeptide (TP-5) on experimental tumors I. TP-5 relieves immunosuppression in tumor-bearing mice. Cell., Immunol. 1982; 66: 127
   Web of Science ®Google Scholar
• Lozzio B B. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 1981; 166: 546
   PubMed Web of Science ®Google Scholar
• Mascart-Lemon F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J. Stimulation of cellulare function by thymopoietin (TP-5) in three AIDS patients. Lancet 1983; 2: 734
   PubMedGoogle Scholar
• Park C H, Amare M, Savin M A, Goodwin J W, Newcomb M M, Hoogstrater B. Growth suppression of human leukemia cells in vitro by L-ascorbic acid. Cancer Res. 1980; 40: 1062
   PubMed Web of Science ®Google Scholar
• Rinaldi-Caraci C, Garaci E, DelGobo V, Favalli C, Jezzi T, Goldstein A L. Modulation of endogenous prostaglandins by thymosin alpha 1 in lymphocytes. Cell Immunol. 1983; 80: 57
   PubMed Web of Science ®Google Scholar
• Rossio J L, Goldstein A L. Immunotherapy of cancer with thymosin. World J. Surg. 1977; 1: 605
   PubMedGoogle Scholar
• Scheld M P, Goldstein G, Hammerling U, Boyse E A. Lymphocyte differentiation from precursor cells in vitro. Ann. NY Acad. Sci. 1975; 249: 531
   PubMed Web of Science ®Google Scholar
• Stannegard O, Stannegard J L, Kang K, Cooper K D, Hanifin J M. Fc IgG receptor-bearing lymphocytes and monoclonal antibody-defined T-cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5). Int. Arch. Allergy Appl. Immunol. 1982; 69: 238
   PubMedGoogle Scholar
• Szende B, Kisfaludy L, Lapis K, Denes L, Szporny L, Nyeki O, Schon I, Hajos G y, Ember J, Constantin M, Paku S, Janossy L. The effect of TP-5 and its analogs on skin grafts in mice. Immunopharmacol 1985; 7: 67
   Google Scholar
• Thivolet J, Faure M, Nicolas J F, Manduit G, Claudy A. Therapeutic use of TP-5 (Thymopoietin 32–36) in sarcodiosis of the skin. Clin. Immunol. Immunopathol. 1983; 26: 350
   PubMedGoogle Scholar
• Tidman N, Janossy G, Bodger M, Granger S, Kung P C, Goldstein G. Delination of human thymocyte differentiation pathways utilizing double-staining techniques with monoclonal antibodies. Clin. Exp. Immunol. 1981; 45: 457
   PubMed Web of Science ®Google Scholar
• Van Wauve J, Goossens J, De Cock W, Kung P C, Goldstein G. Suppression of human T-cell mitogenesis and E-rosette formation by the monoclonal antibody OKT 11A. Immunol. 1981; 44: 865
   PubMed Web of Science ®Google Scholar
• Verbi W, Greaves M F, Schneider C, Koubek K, Janossy G, Stein H, Kung P C, Goldstein G. Monoclonal antibodies OKT 11 and OKT 11A have Pan T reactivity and block sheep erythrocyte “receptors”. Eur. J. Immunol. 1981; 12: 81
   Web of Science ®Google Scholar
• Verhaegen H, De Cock W, De Cree J, Goldstein G. Comparison of the in vitro effects of thymopoietin pentapeptide and levamisole on peripheal E-rosette forming cells. Thymus 1980; 1: 195
   PubMedGoogle Scholar
• Verhaegen H, De Cock W, De Cree J, Goldstein G. Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide. J. Clin. Lab. Immunol. 1981; 6: 103
   PubMedGoogle Scholar
• Veys E M, Huskisson E C, Rosenthal M, Vischer T L, Mielants H, Thrower P A, Scott J, Ott H, Scheijgrond H, Symoens J. Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis. Ann. Rheum. Dis. 1982; 41: 441
   PubMed Web of Science ®Google Scholar
• Wybran J, Dupont E. The active T-rosette: an early marker for T-cell activation. Ann. Immunol., (Inst Pasteur) 1982; 133D: 211
   Google Scholar
• Wybran J, Fudenberg H H. Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and virus infections, and other diseases. J. Clin. Invest. 1973; 52: 1026
   PubMed Web of Science ®Google Scholar
• Yagi Yamashita T, Tsubura E. Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma. Cancer Immunol. Immunother. 1985; 19: 198
   PubMed Web of Science ®Google Scholar
• Zabura K, Rastorfer M, Grob P J, Joller-Jemelka H, Bolla K. Thymopoietin as adjuvant in non-responders or hyporesponders to hepatitis B Vaccination. Lancet 1983; 2: 1245
   Web of Science ®Google Scholar